At the height of the pandemic, Chinese vaccine maker Sinovac was a hero and one of the country’s most promising companies. But its success masked a protracted dispute between rival investors and management for control of the cash-rich company. The Wire China investigates what went wrong.
People receive COVID-19 vaccines at a vaccination site in a stadium in Minhang District, Shanghai, March 28, 2021. Credit: Liu Ying/Xinhua via Getty Images
It was past dusk when Sinovac’s special shareholders meeting kicked off in St. John’s, Antigua on July 8. At a law firm tucked into a back alley, a short drive away from the country's High Court building, a throng of lawyers prepared to square off in the latest round of a years-long fight for control of China’s flagship COVID-19 vaccine maker.
Several tumultuous weeks of legal proceedings had built to this point. The two factions competing for control of Nasdaq-listed Sinovac had be
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
Concrete outcomes are hard to discern, but Xi Jinping will see the treatment he received from Trump as a sign that China is now a peer of the United States.
Corporate Risk Intelligence for National Security, Compliance & Due Diligence
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
